See more : Money3 Corporation Limited (MNY.AX) Income Statement Analysis – Financial Results
Complete financial analysis of bioMérieux S.A. (BMXXY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of bioMérieux S.A., a leading company in the Medical – Specialties industry within the Healthcare sector.
- Firefly Neuroscience Inc. (AIFF) Income Statement Analysis – Financial Results
- Arista Power, Inc. (ASPW) Income Statement Analysis – Financial Results
- Accelya Solutions India Limited (ACCELYA.BO) Income Statement Analysis – Financial Results
- AT&T Inc. 5.35% GLB NTS 66 (TBB) Income Statement Analysis – Financial Results
- Deinove SA (ALDEI.PA) Income Statement Analysis – Financial Results
bioMérieux S.A. (BMXXY)
About bioMérieux S.A.
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.67B | 3.59B | 3.38B | 3.12B | 2.67B | 2.42B | 2.29B | 2.10B | 1.96B | 1.70B | 1.59B | 2.07B |
| Cost of Revenue | 1.62B | 1.63B | 1.41B | 1.38B | 1.23B | 1.14B | 1.09B | 1.02B | 994.00M | 853.90M | 763.30M | 996.24M |
| Gross Profit | 2.06B | 1.96B | 1.97B | 1.74B | 1.45B | 1.28B | 1.19B | 1.08B | 970.60M | 844.50M | 824.60M | 1.07B |
| Gross Profit Ratio | 55.99% | 54.64% | 58.33% | 55.68% | 54.16% | 53.06% | 52.16% | 51.45% | 49.40% | 49.72% | 51.93% | 51.87% |
| Research & Development | 540.30M | 446.60M | 385.80M | 395.70M | 372.50M | 325.50M | 304.40M | 271.90M | 238.90M | 205.80M | 191.80M | 225.46M |
| General & Administrative | 295.00M | 253.20M | 242.10M | 200.00M | 182.20M | 163.20M | 156.40M | 176.19M | 163.80M | 141.70M | 121.40M | 150.70M |
| Selling & Marketing | 725.50M | 701.50M | 573.50M | 589.30M | 567.60M | 479.90M | 447.50M | 402.10M | 365.40M | 311.30M | 283.20M | 388.56M |
| SG&A | 1.02B | 954.70M | 815.60M | 789.30M | 749.80M | 643.10M | 603.90M | 569.50M | 529.80M | 453.00M | 404.60M | 539.26M |
| Other Expenses | 57.50M | 0.00 | 0.00 | 0.00 | 4.50M | 1.80M | 1.60M | 1.20M | 2.00M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.62B | 1.40B | 1.20B | 1.19B | 1.12B | 966.80M | 906.70M | 840.20M | 766.70M | 650.20M | 580.30M | 776.98M |
| Cost & Expenses | 3.24B | 3.03B | 2.61B | 2.57B | 2.34B | 2.10B | 2.00B | 1.86B | 1.76B | 1.50B | 1.34B | 1.77B |
| Interest Income | 1.60M | 1.20M | 1.70M | 1.50M | 1.20M | 21.19M | 17.88M | 16.31M | 16.51M | 8.59M | 1.65M | 1.58M |
| Interest Expense | 4.40M | 4.10M | 9.10M | 24.90M | 22.10M | 19.70M | 16.10M | 17.10M | 17.30M | 14.60M | 1.75M | 882.17K |
| Depreciation & Amortization | 258.90M | 215.23M | 218.07M | 224.77M | 181.94M | 178.37M | 168.33M | 148.30M | 139.00M | 106.00M | 82.00M | 143.71M |
| EBITDA | 700.80M | 832.60M | 1.03B | 779.60M | 558.90M | 517.30M | 449.10M | 419.50M | 342.90M | 332.80M | 344.40M | 486.91M |
| EBITDA Ratio | 19.07% | 22.77% | 29.28% | 25.00% | 20.13% | 21.10% | 19.48% | 19.19% | 17.45% | 19.59% | 21.69% | 23.53% |
| Operating Income | 439.00M | 559.80M | 768.00M | 551.20M | 330.90M | 318.00M | 286.90M | 241.80M | 203.90M | 226.80M | 262.40M | 343.20M |
| Operating Income Ratio | 11.95% | 15.60% | 22.75% | 17.68% | 12.37% | 13.13% | 12.54% | 11.50% | 10.38% | 13.35% | 16.52% | 16.58% |
| Total Other Income/Expenses | -1.50M | -6.70M | -10.50M | -28.60M | -23.40M | -25.50M | 5.60M | -23.20M | -18.30M | -16.40M | -14.40M | -48.26M |
| Income Before Tax | 437.50M | 550.20M | 748.30M | 494.40M | 318.60M | 296.30M | 270.60M | 237.90M | 153.50M | 187.20M | 243.10M | 294.94M |
| Income Before Tax Ratio | 11.91% | 15.33% | 22.16% | 15.86% | 11.91% | 12.24% | 11.83% | 11.31% | 7.81% | 11.02% | 15.31% | 14.25% |
| Income Tax Expense | 114.50M | 109.70M | 149.40M | 91.50M | 48.90M | 41.10M | 32.60M | 58.50M | 42.80M | 51.70M | 78.40M | 117.87M |
| Net Income | 357.60M | 452.30M | 601.10M | 404.40M | 272.80M | 256.50M | 238.10M | 179.10M | 110.50M | 134.90M | 164.30M | 177.20M |
| Net Income Ratio | 9.73% | 12.60% | 17.80% | 12.97% | 10.20% | 10.59% | 10.41% | 8.52% | 5.62% | 7.94% | 10.35% | 8.56% |
| EPS | 3.01 | 3.83 | 5.08 | 3.42 | 2.31 | 2.18 | 2.02 | 1.51 | 0.93 | 1.14 | 1.39 | 1.50 |
| EPS Diluted | 3.01 | 3.82 | 5.06 | 3.41 | 2.30 | 2.17 | 2.02 | 1.51 | 0.93 | 1.14 | 1.39 | 1.50 |
| Weighted Avg Shares Out | 118.80M | 117.95M | 118.27M | 118.15M | 118.30M | 117.79M | 118.13M | 118.35M | 118.35M | 118.33M | 118.48M | 118.24M |
| Weighted Avg Shares Out (Dil) | 118.80M | 118.44M | 118.89M | 118.65M | 118.71M | 118.41M | 118.13M | 118.35M | 118.35M | 118.33M | 118.48M | 118.24M |
Source: https://incomestatements.info
Category: Stock Reports